eculizumab-aagh Bkemv
Selected indexed studies
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2021) [PMID:33730455]
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (N Engl J Med, 2006) [PMID:16990386]
- High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. (MMWR Morb Mortal Wkly Rep, 2017) [PMID:28704351]
_Worker-drafted node — pending editorial review._
Connections
eculizumab-aagh Bkemv is a side effect of
Sources
- High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. (2017) pubmed
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) pubmed
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) pubmed
- A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. (2020) pubmed
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. (2019) pubmed
- Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial. (2023) pubmed
- A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. (2024) pubmed
- Eculizumab. (2006) pubmed
- Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. (2019) pubmed
- Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. (2024) pubmed